Program
Microbial Collagenase
Also written as “EN3835”, “Santyl” and “AA4500”.
Its studies are mostly in Cellulite · Penile Induration · Dupuytren Contracture · Diabetic Foot · Bursitis, led by 5 companies.
Drug pageMicrobial Collagenase: every studyMany companies study it; this page follows only the 42 they lead. All 71 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Keenova Therapeuticsits history only | 382 open or running | phase 4since Dec 17, 2011 | Sep 11, 2007 | Dec 2027phase 3 · NCT07759362 |
| Advance Biofacturesits history only | 10 open or running | phase 1since Aug 22, 2016 | Aug 22, 2016 | none ahead |
| Asahi Kasei Therapeuticsits history only | 10 open or running | phase 3since Apr 27, 2012 | Apr 27, 2012 | none ahead |
| Luxurgeryits history only | 10 open or running | phase 4since Mar 24, 2022 | Mar 24, 2022 | none ahead |
| Manhattan Medical Research Practice, PLLCits history only | 10 open or running | phase 4since Nov 30, 2018 | Nov 30, 2018 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 28 studies since Sep 11, 2007.
- Nov 30, 2018Manhattan Medical Research Practice, PLLC’s first study: phase 4 study in Penile IndurationNew to Manhattan Medical Research Practice, PLLCManhattan Medical Research Practice, PLLC · NCT03767452 · 20 enrolled · United States
- Nov 18, 2019Phase 3 study in CelluliteKeenova Therapeutics · NCT04170296 · 153 enrolled · United States, Puerto Rico
- Dec 11, 2019Phase 2 study in CelluliteKeenova Therapeutics · NCT04209530 · 7 enrolled · United States
- Jan 2, 2020Phase 2 study in Characteristics of Subcutaneous TissueKeenova Therapeutics · NCT04236635 · 10 enrolled · United States
- Jul 29, 2020Phase 2 study in BursitisKeenova Therapeutics · NCT04496167 · 198 enrolled · United States
- Oct 2, 2020Phase 2 study in CelluliteKeenova Therapeutics · NCT04580303 · 35 enrolled · United States
- Nov 29, 2021Phase 2 study in Fibromatosis, PlantarKeenova Therapeutics · NCT05152173 · 176 enrolled · United States
- Feb 15, 2022Phase 3 study in Fibromatosis, PlantarKeenova Therapeutics · NCT05254457 · 145 enrolled · United States
- Mar 24, 2022Luxurgery’s first study: phase 4 study in CelluliteNew to LuxurgeryLuxurgery · NCT05309525 · 17 enrolled · United States
- Jun 9, 2022Phase 2 study in CelluliteKeenova Therapeutics · NCT05419505 · 91 enrolled · United States
- Nov 21, 2023Phase 3 study in Fibromatosis, PlantarKeenova Therapeutics · NCT06151197 · 436 enrolled · United States, Puerto Rico
- Dec 5, 2023Phase 2 study in Fasciitis, PlantarKeenova Therapeutics · NCT06169319 · 231 enrolled · United States
- Aug 7, 2026Phase 3 study in Flexible HammertoeKeenova Therapeutics · NCT07759362 · 554 planned · United States
- Sep 23, 2026Phase 3 study in Flexible HammertoeKeenova Therapeutics · NCT07846280 · 470 planned · United States
Ahead
- Dec 2027Primary completion: phase 3 study in Flexible HammertoeKeenova Therapeutics · NCT07759362
- Dec 2028Primary completion: phase 3 study in Flexible HammertoeKeenova Therapeutics · NCT07846280
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 42 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07846280Flexible Hammertoe · United States | 3 | Recruiting | Keenova Therapeutics | Dec 2028 | 470 |
| NCT07759362Flexible Hammertoe · United States | 3 | Recruiting | Keenova Therapeutics | Dec 2027 | 554 |
| NCT06169319Fasciitis, Plantar · United States | 2 | Completed | Keenova Therapeutics | Sep 30, 2024 | 231 |
| NCT06151197Fibromatosis, Plantar · United States, Puerto Rico | 3 | Completed | Keenova Therapeutics | Jun 9, 2026 | 436 |
| NCT05419505Cellulite · United States | 2 | Completed | Keenova Therapeutics | Jan 3, 2023 | 91 |
| NCT05309525Cellulite · United States | 4 | Completed | Luxurgery | Sep 1, 2022 | 17 |
| NCT05254457Fibromatosis, Plantar · United States | 3 | Completed | Keenova Therapeutics | Mar 21, 2024 | 145 |
| NCT05152173Fibromatosis, Plantar · United States | 2 | Completed | Keenova Therapeutics | Jan 10, 2023 | 176 |
| NCT04580303Cellulite · United States | 2 | Completed | Keenova Therapeutics | Aug 30, 2021 | 35 |
| NCT04496167Bursitis · United States | 2 | Completed | Keenova Therapeutics | Apr 14, 2022 | 198 |
| NCT04236635Characteristics of Subcutaneous Tissue · United States | 2 | Completed | Keenova Therapeutics | Sep 23, 2020 | 10 |
| NCT04209530Cellulite · United States | 2 | Terminated | Keenova Therapeutics | Jul 23, 2020 | 7 |
| NCT04170296Cellulite · United States, Puerto Rico | 3 | Completed | Keenova Therapeutics | Oct 6, 2020 | 153 |
| NCT03767452Penile Induration · United States | 4 | UNKNOWN | Manhattan Medical Research Practice, PLLC | Dec 2019 | 20 |
| NCT03675685Cellulite · United States | 1 | Completed | Keenova Therapeutics | Nov 1, 2018 | 12 |
| NCT03632993Cellulite · United States | 2 | Completed | Keenova Therapeutics | Jan 24, 2019 | 64 |
| NCT03526549Cellulite · United States | 3 | Completed | Keenova Therapeutics | Oct 8, 2021 | 483 |
| NCT03446781Cellulite · United States | 3 | Completed | Keenova Therapeutics | Sep 26, 2018 | 422 |
| NCT03428750Cellulite · United States | 3 | Completed | Keenova Therapeutics | Sep 26, 2018 | 423 |
| NCT03329989Cellulite · United States | 2 | Completed | Keenova Therapeutics | Sep 5, 2018 | 158 |
| NCT02942160Cellulite · United States | 2 | Completed | Keenova Therapeutics | Jun 14, 2018 | 259 |
| NCT02889848Leiomyoma · United States | 1 | Completed | Advance Biofactures | Oct 5, 2018 | 15 |
| NCT02724644Cellulite · United States | 2 | Completed | Keenova Therapeutics | Sep 2016 | 375 |
| NCT02193828Dupuytren Contracture · United States, Australia | 2 | Completed | Keenova Therapeutics | Dec 2014 | 76 |
| NCT02006719Bursitis · United States, Australia | 2 | Completed | Keenova Therapeutics | Dec 2014 | 322 |
| NCT01987986Cellulite · United States | 2 | Completed | Keenova Therapeutics | Aug 2014 | 150 |
| NCT01685437Penile Induration | 3 | Completed | Keenova Therapeutics | Dec 2013 | 189 |
| NCT01588353Dupuytren Contracture · Japan | 3 | Completed | Asahi Kasei Therapeutics | Jan 2014 | 104 |
| NCT01518907Cellulite · United States | 1 | Completed | Keenova Therapeutics | Dec 2012 | 99 |
| NCT01498640Dupuytren Contracture · United States, Australia, Sweden and more | 4 | Completed | Keenova Therapeutics | Oct 2013 | 52 |
| NCT01483963Bursitis · United States | 2 | Completed | Keenova Therapeutics | Feb 2013 | 50 |
| NCT01430169Penile Induration · United States | 2 | Completed | Keenova Therapeutics | Nov 2011 | 20 |
| NCT01407068Dupuytren Contracture · United States, Australia | 3 | Completed | Keenova Therapeutics | Feb 2012 | 60 |
| NCT01243411Penile Induration · United States, Denmark, France and more | 3 | Completed | Keenova Therapeutics | Aug 2012 | 348 |
| NCT01221623Penile Induration · United States, Australia | 3 | Completed | Keenova Therapeutics | Mar 2012 | 418 |
| NCT01221597Penile Induration · United States, Australia | 3 | Completed | Keenova Therapeutics | Apr 2012 | 418 |
| NCT00755222Penile Induration · United States | 2 | Completed | Keenova Therapeutics | Dec 2009 | 147 |
| NCT00533273Advanced Dupuytren's Disease · Australia | 3 | Completed | Keenova Therapeutics | Sep 2008 | 66 |
| NCT00528931Dupuytren Contracture · United States | 1 | Completed | Keenova Therapeutics | Dec 2007 | 16 |
| NCT00528840Advanced Dupuytren's Disease · United States | 3 | Completed | Keenova Therapeutics | Oct 2008 | 201 |
| NCT00528606Dupuytren Contracture · United States | 3 | Completed | Keenova Therapeutics | Apr 2008 | 308 |
| NCT00528424Advanced Dupuytren's Disease · United States | 3 | Completed | Keenova Therapeutics | Nov 2008 | 286 |
How it is read
Names in the registry
- “EN3835”, 9 entries
- “Santyl”, 7 entries
- “AA4500”, 7 entries
- “collagenase clostridium histolyticum”, 5 entries
- “Collagenase Clostridium Histolyticum”, 5 entries
Conditions, from the studies’ own filings
- Cellulite, 15 studies
- Penile Induration, 7 studies
- Dupuytren Contracture, 6 studies
- Diabetic Foot, 5 studies
- Bursitis, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.